PCM
SLXP

Portolan Capital Management’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Portolan Capital Management’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-5,026
Closed -$336K – 155
2013
Q3 		$336K Hold
5,026
– – 0.09% 114
2013
Q2 		$332K Buy
+5,026
New +$287K 0.09% 139

Other funds holding SLXP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Portolan Capital Management's SLXP Position: Q4 2013 in Review

Portolan Capital Management sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q4 2013, closing a stake of 5,026 shares — an estimated $336K sold.

Portolan Capital Management first reported a position in SLXP in Q2 2013 and held it in 2 quarters. The position peaked at $336K in Q3 2013. 245 funds tracked by Wall St. Rank hold SLXP as of Q4 2013.

  • Portolan Capital Management reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q4 2013 after selling out during the quarter.
  • Portolan Capital Management sold 5,026 SALIX PHARMACEUTICALS LTD DEL shares in Q4 2013, an estimated $336K.
  • Portolan Capital Management first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 2 quarters.
  • Portolan Capital Management's SALIX PHARMACEUTICALS LTD DEL position peaked at $336K in Q3 2013.
  • 245 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q4 2013.

Based on Portolan Capital Management's 13F filing for Q4 2013, filed 13 Feb 2014.